CUE

CUE

USD

Cue Biopharma Inc. Common Stock

$0.639+0.011 (1.752%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$0.628

Максимум

$0.660

Минимум

$0.620

Объем

0.10M

Фундаментальные показатели компании

Рыночная капитализация

48.1M

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

0.16M

Биржа

NCM

Валюта

USD

52-недельный диапазон

Минимум $0.45Текущая $0.639Максимум $1.989

Связанные новости

GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Просмотреть больше
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Просмотреть больше
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Просмотреть больше
Cue Biopharma to Host Business Update Call and Webcast
GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Просмотреть больше
Cue Biopharma Announces Proposed Public Offering
GlobeNewswire

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses on further research and development of a novel,

Просмотреть больше
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.